Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.

Nature communications - 28 Apr 2016

Brooun Alexei, Gajiwala Ketan S, Deng Ya-Li, Liu Wei, Bolaños Ben, Bingham Patrick, He You-Ai, Diehl Wade, Grable Nicole, Kung Pei-Pei, Sutton Scott, Maegley Karen A, Yu Xiu, Stewart Al E

Abstract excerpt

Polycomb repressive complex 2 (PRC2) mediates gene silencing through chromatin reorganization by methylation of histone H3 lysine 27 (H3K27). Overexpression of the complex and point mutations in the individual subunits of PRC2 have been shown to contribute to tumorigenesis. Several inhibitors of the PRC2 activity have shown efficacy in EZH2-mutated lymphomas and are currently in clinical development, although the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enhancer of Zeste Homolog 2 Protein

Share to Enzyme Inhibitors

Share to Models, Molecular

Share to Mutation

Share to Neoplasms

Share to Polycomb Repressive Complex 2

Source

Open in PubMed Open full text

Identifiers

PMID: 27122193
DOI: 10.1038/ncomms11384
PMCID: PMC4853478

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.PMID 27122193Read ↗

Structure of the PRC2 complex and application to drug discovery.Semantic proximity Read ↗

Allosteric activation dictates PRC2 activity independent of its recruitment to chromatinSemantic proximity Read ↗

Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.Semantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).Semantic proximity Read ↗

Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.Semantic proximity Read ↗

Structural assembly of Polycomb group protein and Insight of EZH2 in cancer progression: A review.Semantic proximity Read ↗

Targeting EZH2 in cancer.Semantic proximity Read ↗

Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.Semantic proximity Read ↗

Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor TypesSemantic proximity Read ↗

Regulation of histone methylation by automethylation of PRC2Semantic proximity Read ↗

Epigenetic vulnerabilities of leukemia harboring inactivating EZH2 mutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.